|
|
Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches |
Min Yu, Zonghai Li() |
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China |
|
|
Abstract Hepatocellular carcinoma (HCC) is currently the fifth most common malignancy and the third leading cause of cancer-related mortalities worldwide. In the last few years, treatments for HCC have significantly improved from a mere surgical resection to a series of minimally invasive therapies and targeted drugs. However, recurrence frequently occurs even upon curative therapeutics, and drug therapies generally produce disappointing results, with the overall prognosis dismal. This challenging clinical scenario warrants new effective and life-prolonging strategies for patients with HCC. Compelling evidence suggests that NK cells play a critical role in the immune function of the liver and in the immune defenses against HCC, indicating that HCC might be an ideal target for NK cell-based immunotherapies. To obtain comprehensive insights into the putative influence of NK cells on HCC, this paper summarizes current knowledge on NK cells in HCC and discusses the usefulness and prospects of NK cell-based immunotherapies. Critical issues that require consideration for the successful clinical translation of NK cell-based therapies are also addressed. If appropriately used and further optimized, NK cell-based therapies could dominate important roles in the future immunotherapeutic market of HCC.
|
Keywords
natural killer cell
hepatocellular carcinoma
immunotherapy
|
Corresponding Author(s):
Zonghai Li
|
Just Accepted Date: 30 June 2017
Online First Date: 04 August 2017
Issue Date: 04 December 2017
|
|
1 |
Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012; 62(6): 394–399
https://doi.org/10.3322/caac.21161
pmid: 23070690
|
2 |
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150(4): 835–853
https://doi.org/10.1053/j.gastro.2015.12.041
pmid: 26795574
|
3 |
Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 2014; 11(9): 525–535
https://doi.org/10.1038/nrclinonc.2014.122
pmid: 25091611
|
4 |
Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015; 62(5): 1187–1195
https://doi.org/10.1016/j.jhep.2015.02.010
pmid: 25681552
|
5 |
Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015; 12(7): 408–424
https://doi.org/10.1038/nrclinonc.2015.103
pmid: 26054909
|
6 |
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480(7378): 480–489
https://doi.org/10.1038/nature10673
pmid: 22193102
|
7 |
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9(5): 503–510
https://doi.org/10.1038/ni1582
pmid: 18425107
|
8 |
Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 2015; 15(4): 243–254
https://doi.org/10.1038/nri3799
pmid: 25743219
|
9 |
Herberman RB, Reynolds CW, Ortaldo JR. Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol 1986; 4(1): 651–680
https://doi.org/10.1146/annurev.iy.04.040186.003251
pmid: 3518752
|
10 |
Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008; 8(9): 713–725
https://doi.org/10.1038/nri2381
pmid: 19172692
|
11 |
de Saint Basile G, Ménasché G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 2010; 10(8): 568–579
https://doi.org/10.1038/nri2803
pmid: 20634814
|
12 |
Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PMNK. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 2015; 6: 368
https://doi.org/10.3389/fimmu.2015.00368
pmid: 26284063
|
13 |
Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004; 104(1): 170–177
https://doi.org/10.1182/blood-2003-12-4438
pmid: 15016654
|
14 |
Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socié G, Rio B, Sirvent A, Renaud M, Madero L, Mohty M, Ferra C, Garnier F, Loiseau P, Garcia J, Lecchi L, Kögler G, Beguin Y, Navarrete C, Devos T, Ionescu I, Boudjedir K, Herr AL, Gluckman E, Rocha V; Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT.KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23(3): 492–500
https://doi.org/10.1038/leu.2008.365
pmid: 19151783
|
15 |
Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28(6): 955–959
https://doi.org/10.1200/JCO.2009.24.4590
pmid: 20085940
|
16 |
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7(1): 94–100
https://doi.org/10.1038/83416
pmid: 11135622
|
17 |
Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011; 11(10): 658–671
https://doi.org/10.1038/nri3065
pmid: 21941294
|
18 |
Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012; 61(3): 427–438
https://doi.org/10.1136/gutjnl-2011-300509
pmid: 21930732
|
19 |
Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006; 43(2): 362–372
https://doi.org/10.1002/hep.21035
pmid: 16440347
|
20 |
Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52(3): 370–379
https://doi.org/10.1016/j.jhep.2009.07.013
pmid: 19720422
|
21 |
Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 2016; 67: 103–117
https://doi.org/10.1146/annurev-med-090514-013832
pmid: 26473416
|
22 |
Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology 2013; 57(4): 1654–1662
https://doi.org/10.1002/hep.26115
pmid: 23111952
|
23 |
Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis 2011; 32(10): 1434–1440
https://doi.org/10.1093/carcin/bgr133
pmid: 21771728
|
24 |
Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, Zhang H, Yang Y, Wu H, Tien P, Wang FS. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129(3): 428–437
https://doi.org/10.1016/j.clim.2008.08.012
pmid: 18824414
|
25 |
Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009; 86(3): 513–528
https://doi.org/10.1189/JLB.0309135
pmid: 19542050
|
26 |
He L, Wang X, Montell DJ. Shining light on Drosophila oogenesis: live imaging of egg development. Curr Opin Genet Dev 2011; 21(5): 612–619
https://doi.org/10.1016/j.gde.2011.08.011
pmid: 21930372
|
27 |
Chirinda W, Chen H. Comparative study of disability-free life expectancy across six low- and middle-income countries. Geriatr Gerontol Int 2017; 17(4): 637–644
https://doi.org/10.1111/ggi.12748
pmid: 27197085
|
28 |
Une Y, Kawata A, Uchino J. Adopted immunochemotherapy using IL-2 and spleen LAK cell—randomized study. Nihon Geka Gakkai Zasshi 1991; 92(9): 1330–1333 (in Japanese)
pmid: 1658591
|
29 |
Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 1995; 15(2): 543–550
pmid: 7539237
|
30 |
Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, Uchino J, Kobayashi H. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 1995; 18(3): 257–262
https://doi.org/10.1097/00000421-199506000-00014
pmid: 7747715
|
31 |
Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31(1): 227–258
https://doi.org/10.1146/annurev-immunol-020711-075005
pmid: 23516982
|
32 |
Beneker C. Report from Hannover. Family practitioners in emergency admission. MMW Fortschr Med 2015; 157(1): 8–9 (in German)
https://doi.org/10.1007/s15006-015-2560-1
pmid: 25743279
|
33 |
Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23(1): 225–274
https://doi.org/10.1146/annurev.immunol.23.021704.115526
pmid: 15771571
|
34 |
Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol 2015; 33(1): 445–474
https://doi.org/10.1146/annurev-immunol-032414-112043
pmid: 25622193
|
35 |
Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016; 17(9): 1025–1036
https://doi.org/10.1038/ni.3518
pmid: 27540992
|
36 |
Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3(10): 781–790
https://doi.org/10.1038/nri1199
pmid: 14523385
|
37 |
Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007; 7(9): 737–744
https://doi.org/10.1038/nri2144
pmid: 17673918
|
38 |
Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43(6): 1013–1020
https://doi.org/10.1016/j.jhep.2005.05.026
pmid: 16168521
|
39 |
Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, Inoue M, Wakai T, Shirai Y, Nomoto M, Aoyagi Y. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol 2012; 56(2): 381–388
https://doi.org/10.1016/j.jhep.2011.06.017
pmid: 21756848
|
40 |
Gao J, Duan Z, Zhang L, Huang X, Long L, Tu J, Liang H, Zhang Y, Shen T, Lu F. Failure recovery of circulating NKG2D(+)CD56(dim)NK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrence. OncoImmunology 2016; 5(1): e1048061
https://doi.org/10.1080/2162402X.2015.1048061
pmid: 26942056
|
41 |
Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009; 50(3): 799–807
https://doi.org/10.1002/hep.23054
pmid: 19551844
|
42 |
Qu P, Huang X, Zhou X, Lü Z, Liu F, Shi Z, Lü L, Wu Y, Chen Y. Loss of CD155 expression predicts poor prognosis in hepatocellular carcinoma. Histopathology 2015; 66(5): 706–714
https://doi.org/10.1111/his.12584
pmid: 25320021
|
43 |
Tanimine N, Ohdan H. Impact of multiplicity of functional KIR-HLA compound genotypes on hepatocellular carcinoma. OncoImmunology 2015; 4(1): e983765
https://doi.org/10.4161/2162402X.2014.983765
pmid: 25949863
|
44 |
Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20(1): 217–251
https://doi.org/10.1146/annurev.immunol.20.092501.134942
pmid: 11861603
|
45 |
Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001; 19(1): 291–330
https://doi.org/10.1146/annurev.immunol.19.1.291
pmid: 11244039
|
46 |
Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436(7051): 709–713
https://doi.org/10.1038/nature03847
pmid: 16079848
|
47 |
Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, Zanelli P, Zanetti A, Trenti T, Ferrari C, Missale G. HLA and killer immunoglobulin-like receptor genes as outcome predictors of hepatitis C virus-related hepatocellular carcinoma. Clin Cancer Res 2013; 19(19): 5465–5473
https://doi.org/10.1158/1078-0432.CCR-13-0986
pmid: 23938290
|
48 |
Tanimine N, Tanaka Y, Kobayashi T, Tashiro H, Miki D, Imamura M, Aikata H, Tanaka J, Chayama K, Ohdan H. Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy. Cancer Immunol Res 2014; 2(12): 1142–1147
https://doi.org/10.1158/2326-6066.CIR-14-0091
pmid: 25135909
|
49 |
Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13(12): 1770–1787
https://doi.org/10.3748/wjg.v13.i12.1770
pmid: 17465466
|
50 |
Jamil KM, Khakoo SI. KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol 2011; 2011: 298348
https://doi.org/10.1155/2011/298348
pmid: 21629750
|
51 |
Pan N, Jiang W, Sun H, Miao F, Qiu J, Jin H, Xu J, Shi Q, Xie W, Zhang J. KIR and HLA loci are associated with hepatocellular carcinoma development in patients with hepatitis B virus infection: a case-control study. PLoS One 2011; 6(10): e25682
https://doi.org/10.1371/journal.pone.0025682
pmid: 21998681
|
52 |
Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1(1): 23–61
https://doi.org/10.1146/annurev.pathol.1.110304.100230
pmid: 18039107
|
53 |
Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016; 16(8): 509–523
https://doi.org/10.1038/nri.2016.69
pmid: 27374637
|
54 |
Pan N, Qiu J, Sun H, Miao F, Shi Q, Xu J, Jiang W, Jin H, Xie W, He Y, Zhang J. Combination of human leukecyte antigen and killer cell immunoglulin-like antigen and killer cell influences the onset age of hepatocellular carcinoma in male patients with hepatitis B virus infenction. Clin Dev Immunol 2013; 2013: 874514
|
55 |
De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, Tornesello ML, Buonaguro FM, Mangia A, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Vaccher E, Berretta M, Mazzaro C, Libra M, Gini A, Zucchetto A, Cannizzaro R, De Paoli P. Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. PLoS One 2015; 10(2): e0117420
https://doi.org/10.1371/journal.pone.0117420
pmid: 25700262
|
56 |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331(6024): 1565–1570
https://doi.org/10.1126/science.1203486
pmid: 21436444
|
57 |
Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer 2012; 118(16): 3984–3992
https://doi.org/10.1002/cncr.26726
pmid: 22180222
|
58 |
Chen Z, Xie B, Zhu Q, Xia Q, Jiang S, Cao R, Shi L, Qi D, Li X, Cai L. FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis. Int J Med Sci 2013; 10(13): 1868–1875
https://doi.org/10.7150/ijms.6868
pmid: 24324363
|
59 |
Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol 2015; 62(6): 1420–1429
https://doi.org/10.1016/j.jhep.2015.02.038
pmid: 25733155
|
60 |
Lin TH, Shao YY, Chan SY, Huang CY, Hsu CH, Cheng AL. High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib. Clin Cancer Res 2015; 21(16): 3678–3684
https://doi.org/10.1158/1078-0432.CCR-14-1954
pmid: 25977342
|
61 |
Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14(6): e218–e228
https://doi.org/10.1016/S1470-2045(12)70582-X
pmid: 23639322
|
62 |
Mouri H, Sakaguchi K, Sawayama T, Senoh T, Ohta T, Nishimura M, Fujiwara A, Terao M, Shiratori Y, Tsuji T. Suppressive effects of transforming growth factor-beta1 produced by hepatocellular carcinoma cell lines on interferon-γ production by peripheral blood mononuclear cells. Acta Med Okayama 2002; 56(6): 309–315
pmid: 12685860
|
63 |
Sui Q, Zhang J, Sun X, Zhang C, Han Q, Tian Z. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J Immunol 2014; 193(4): 2016–2023
https://doi.org/10.4049/jimmunol.1302389
pmid: 25015826
|
64 |
Xu D, Han Q, Hou Z, Zhang C, Zhang J. miR-146a negatively regulates NK cell functions via STAT1 signaling. Cell Mol Immunol2016 Mar 21. [Epub ahead of print] doi: 10.1038/cmi.2015.113
https://doi.org/10.1038/cmi.2015.113
pmid: 26996068
|
65 |
Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144(3): 512–527
https://doi.org/10.1053/j.gastro.2013.01.002
pmid: 23313965
|
66 |
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu YX, Wang FS. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132(7): 2328–2339
https://doi.org/10.1053/j.gastro.2007.03.102
pmid: 17570208
|
67 |
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25(18): 2586–2593
https://doi.org/10.1200/JCO.2006.09.4565
pmid: 17577038
|
68 |
Langhans B, Alwan AW, Krämer B, Glässner A, Lutz P, Strassburg CP, Nattermann J, Spengler U. Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. J Hepatol 2015; 62(2): 398–404
https://doi.org/10.1016/j.jhep.2014.08.038
pmid: 25195554
|
69 |
Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 2015; 128: 95–139
https://doi.org/10.1016/bs.acr.2015.04.002
pmid: 26216631
|
70 |
Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology 2015; 62(4): 1304–1312
https://doi.org/10.1002/hep.27867
pmid: 25914264
|
71 |
Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8(9): 705–713
https://doi.org/10.1038/nrc2468
pmid: 19143055
|
72 |
Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009; 9(9): 609–617
https://doi.org/10.1038/nri2607
pmid: 19704417
|
73 |
Hasmim M, Messai Y, Ziani L, Thiery J, Bouhris JH, Noman MZ, Chouaib S. Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress. Front Immunol 2015; 6: 482
https://doi.org/10.3389/fimmu.2015.00482
pmid: 26441986
|
74 |
Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, Schivazappa S, Zibera C, Fagnoni FF, Ferrari C, Missale G. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66(2): 1139–1146
https://doi.org/10.1158/0008-5472.CAN-05-2244
pmid: 16424051
|
75 |
Mizukoshi E, Yamashita T, Arai K, Sunagozaka H, Ueda T, Arihara F, Kagaya T, Yamashita T, Fushimi K, Kaneko S. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 2013; 57(4): 1448–1457
https://doi.org/10.1002/hep.26153
pmid: 23174905
|
76 |
Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C, Missale G. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 2010; 138(5): 1931–1942
https://doi.org/10.1053/j.gastro.2009.12.051
pmid: 20060829
|
77 |
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–390
https://doi.org/10.1056/NEJMoa0708857
pmid: 18650514
|
78 |
Tomuleasa C, Giannelli G, Cucuianu A, Aldea M, Paradiso A, Berindan-Neagoe I. Interplay between cancer cells, macrophages and natural killer cells may actually decide the outcome of therapy with sorafenib. Hepatology 2014; 60(1): 430
https://doi.org/10.1002/hep.26907
pmid: 24338511
|
79 |
Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010; 51(4): 1264–1273
https://doi.org/10.1002/hep.23456
pmid: 20099300
|
80 |
Zhang QB, Sun HC, Zhang KZ, Jia QA, Bu Y, Wang M, Chai ZT, Zhang QB, Wang WQ, Kong LQ, Zhu XD, Lu L, Wu WZ, Wang L, Tang ZY. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS One 2013; 8(2): e55945
https://doi.org/10.1371/journal.pone.0055945
pmid: 23409093
|
81 |
Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013; 57(6): 2358–2368
https://doi.org/10.1002/hep.26328
pmid: 23424039
|
82 |
Kamiya T, Chang YH, Campana D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer Immunol Res 2016; 4(7): 574–581
https://doi.org/10.1158/2326-6066.CIR-15-0229
pmid: 27197065
|
83 |
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9(11): 798–809
https://doi.org/10.1038/nrc2734
pmid: 19851315
|
84 |
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7(1): 41–51
https://doi.org/10.1038/nri1995
pmid: 17186030
|
85 |
Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 2008; 14(11): 3520–3528
https://doi.org/10.1158/1078-0432.CCR-07-4744
pmid: 18519785
|
86 |
Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer Lett 2016; 373(1): 45–56
https://doi.org/10.1016/j.canlet.2016.01.017
pmid: 26805759
|
87 |
Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015; 12(12): 681–700
https://doi.org/10.1038/nrgastro.2015.173
pmid: 26484443
|
88 |
Takeda T, Watanabe M, Umeshita K, Goto M, Monden M. Long-term prognosis of hepatocellular carcinoma patients treated with adoptive immunotherapy. Gan To Kagaku Ryoho 2004; 31(11): 1646–1648 (in Japanese)
pmid: 15553671
|
89 |
Hsieh KH, Chang JS, Wu HL, Chu CT. Interleukin 2 and lymphokine-activated killer cells in the treatment of childhood primary hepatocellular carcinoma—a preliminary report. Asian Pac J Allergy Immunol 1987; 5(1): 13–16
pmid: 3040030
|
90 |
Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother 2013; 36(5): 287–293
https://doi.org/10.1097/CJI.0b013e3182948452
pmid: 23719239
|
91 |
Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC, Li SP, Lau WY. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. OncoImmunology 2015; 5(3): e1083671
https://doi.org/10.1080/2162402X.2015.1083671
pmid: 27141337
|
92 |
Li X, Dai D, Song X, Liu J, Zhu L, Xu W. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2014; 38(5): 583–591
https://doi.org/10.1016/j.clinre.2014.04.010
pmid: 24924902
|
93 |
He G, Zheng C, Huo H, Zhang H, Zhu Z, Li J, Zhang H. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis. Int Immunopharmacol 2016; 40: 436–442
https://doi.org/10.1016/j.intimp.2016.09.015
pmid: 27716591
|
94 |
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148(7): 1383–91.e6
https://doi.org/10.1053/j.gastro.2015.02.055
pmid: 25747273
|
95 |
Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69(9): 4010–4017
https://doi.org/10.1158/0008-5472.CAN-08-3712
pmid: 19383914
|
96 |
Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 2015; 17(5): 621–632
https://doi.org/10.1016/j.jcyt.2015.03.611
pmid: 25881519
|
97 |
Lim O, Jung MY, Hwang YK, Shin EC. Present and future of allogeneic natural killer cell therapy. Front Immunol 2015; 6: 286
https://doi.org/10.3389/fimmu.2015.00286
pmid: 26089823
|
98 |
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295(5562): 2097–2100
https://doi.org/10.1126/science.1068440
pmid: 11896281
|
99 |
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105(8): 3051–3057
https://doi.org/10.1182/blood-2004-07-2974
pmid: 15632206
|
100 |
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356(9232): 802–807
https://doi.org/10.1016/S0140-6736(00)02654-4
pmid: 11022927
|
101 |
Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H, Ishiyama K, Zhou W, Tanaka Y, Asahara T. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 2004; 39(5): 1321–1331
https://doi.org/10.1002/hep.20204
pmid: 15122761
|
102 |
Nishida S, Levi DM, Tzakis AG. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma. Curr Opin Organ Transplant 2013; 18(6): 690–694
pmid: 24220052
|
103 |
Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother 2016; 65(4): 485–492
https://doi.org/10.1007/s00262-015-1761-x
pmid: 26559813
|
104 |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252–264
https://doi.org/10.1038/nrc3239
pmid: 22437870
|
105 |
Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 2014; 60(5): 1776–1782
https://doi.org/10.1002/hep.27246
pmid: 24912948
|
106 |
Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 2017; 139(1): 335–346.e3
https://doi.org/10.1016/j.jaci.2016.04.025
pmid: 27372564
|
107 |
Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014; 99(6): e81–e83
https://doi.org/10.3324/haematol.2013.103085
pmid: 24658821
|
108 |
Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, Landgren O, Childs RW. Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin Cancer Res 2016; 22(21): 5211–5222
https://doi.org/10.1158/1078-0432.CCR-16-1108
pmid: 27307594
|
109 |
Felices M, Miller JS. Targeting KIR blockade in multiple myeloma: trouble in checkpoint paradise? Clin Cancer Res 2016; 22(21): 5161–5163
https://doi.org/10.1158/1078-0432.CCR-16-1582
pmid: 27430580
|
110 |
Ruggeri L, Urbani E, André P, Mancusi A, Tosti A, Topini F, Bléry M, Animobono L, Romagné F, Wagtmann N, Velardi A. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica 2016; 101(5): 626–633
https://doi.org/10.3324/haematol.2015.135301
pmid: 26721894
|
111 |
Chen A, Shen Y, Xia M, Xu L, Pan N, Yin Y, Miao F, Shen C, Xie W, Zhang J. Expression of the nonclassical HLA class I and MICA/B molecules in human hepatocellular carcinoma. Neoplasma 2011; 58(5): 371–376
https://doi.org/10.4149/neo_2011_05_371
pmid: 21744989
|
112 |
Casadevall A, Pirofski LA. A new synthesis for antibody-mediated immunity. Nat Immunol 2011; 13(1): 21–28
https://doi.org/10.1038/ni.2184
pmid: 22179281
|
113 |
Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125(1): 89–97
https://doi.org/10.1016/S0016-5085(03)00689-9
pmid: 12851874
|
114 |
Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009; 378(2): 279–284
https://doi.org/10.1016/j.bbrc.2008.11.033
pmid: 19022220
|
115 |
Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013; 19(4): 920–928
https://doi.org/10.1158/1078-0432.CCR-12-2616
pmid: 23362325
|
116 |
Felices M, Lenvik TR, Davis ZB, Miller JS, Vallera DA. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol Biol 2016; 1441: 333–346
https://doi.org/10.1007/978-1-4939-3684-7_28
pmid: 27177679
|
117 |
Tay SS, Carol H, Biro M. TriKEs and BiKEs join CARs on the cancer immunotherapy highway. Hum Vaccin Immunother 2016; 12(11): 2790–2796
https://doi.org/10.1080/21645515.2016.1198455
pmid: 27322989
|
118 |
Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res 2016; 22(14): 3440–3450
https://doi.org/10.1158/1078-0432.CCR-15-2710
pmid: 26847056
|
119 |
Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA. Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther 2016; 24(7): 1312–1322
https://doi.org/10.1038/mt.2016.88
pmid: 27157665
|
120 |
Mariani E, Meneghetti A, Tarozzi A, Cattini L, Facchini A. Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: the synergistic effect of interleukin-2. Scand J Immunol 2000; 51(6): 618–625
https://doi.org/10.1046/j.1365-3083.2000.00737.x
pmid: 10849374
|
121 |
Jiang W, Zhang C, Tian Z, Zhang J. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Gene Ther 2013; 20(11): 1062–1069
https://doi.org/10.1038/gt.2013.31
pmid: 23759701
|
122 |
Jiang W, Zhang C, Tian Z, Zhang J. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo. Immunobiology 2014; 219(7): 547–553
https://doi.org/10.1016/j.imbio.2014.03.007
pmid: 24721706
|
123 |
Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 2013; 73(6): 1777–1786
https://doi.org/10.1158/0008-5472.CAN-12-3558
pmid: 23302231
|
124 |
Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol 2015; 6: 195
https://doi.org/10.3389/fimmu.2015.00195
pmid: 25972867
|
125 |
Klingemann H. Are natural killer cells superior CAR drivers? OncoImmunology 2014; 3(4): e28147
https://doi.org/10.4161/onci.28147
pmid: 25340009
|
126 |
Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 2012; 16(3): 569–581
https://doi.org/10.1111/j.1582-4934.2011.01343.x
pmid: 21595822
|
127 |
Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. OncoImmunology 2013; 2(10): e26527
https://doi.org/10.4161/onci.26527
pmid: 24404423
|
128 |
Zhang C, Burger MC, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS. ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst 2016; 108(5): djv375
pmid: 26640245
|
129 |
Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014; 20(24): 6418–6428
https://doi.org/10.1158/1078-0432.CCR-14-1170
pmid: 25320357
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|